Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Clinical trial NCT04925544 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT04925544

Sponsor

Stanford University

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2022-01-25

Primary completion

2026-06-17

Enrollment

13

View on ClinicalTrials.gov